Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 88Neoplasms 6HER2-positive Breast Cancer 5Triple Negative Breast Neoplasms 4Prostatic Neoplasms 4Ovarian Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Stomach Neoplasms 3Neoplasm Metastasis 3Multiple Myeloma 3Colorectal Neoplasms 3Urinary Bladder Neoplasms 2Rectal Neoplasms 2Pathologic Complete Response 2Pancreatic Neoplasms 2Lymphoma, Non-Hodgkin 2Lung Neoplasms 2Locally Advanced Breast Cancer 2Inflammatory Breast Neoplasms 2Colonic Neoplasms 2Brain Neoplasms 2Biliary Tract Neoplasms 2Anatomic Stage I Breast Cancer AJCC v8 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Thyroid Neoplasms 1Solid Cancers 1Salivary Gland Neoplasms 1Neuroendocrine Tumors 1Neuroblastoma 1

Interventions

pyrotinib 1pertuzumab 1Trastuzumab 1Surgical Procedures, Operative 1Mastectomy 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Breast Cancer Invasive × pertuzumab × Clear all
NCT04398914 2022-03-31

Pyrotinib, Trastuzumab, Pertuzumab and Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer

Shanghai Jiao Tong University School of Medicine

Phase 2 Active not recruiting
216 enrolled
Breast

Breast Cancer Invasive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡